Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia
- 1 November 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 34 (11), 2898-2902
- https://doi.org/10.1038/s41375-020-0895-9
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized StudyJournal of Clinical Oncology, 2019
- Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysisHaematologica, 2019
- Acute Lymphoblastic Leukemia in ChildrenThe New England Journal of Medicine, 2015
- The potential of clofarabine in MLL -rearranged infant acute lymphoblastic leukaemiaEuropean Journal of Cancer, 2015
- Gene expression profiling–based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infantsBlood, 2010
- A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trialThe Lancet, 2007
- In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotypeLeukemia, 2004
- Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemiaBlood, 2002
- Nucleoside analogues and nucleobases in cancer treatmentThe Lancet Oncology, 2002
- Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia–implications for treatment of infantsLeukemia, 1998